Compare Eli Lilly And Co (LLY) vs Starbucks Corp (SBUX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Starbucks Corp — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while Starbucks Corp trades at $90.75 (market cap $106.26B). The key difference: Eli Lilly And Co is far larger — about 9.8× Starbucks Corp's market cap, and Starbucks Corp pays the higher dividend (2.7%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Starbucks Corp for 190 Days on average.
| LLY | SBUX | |
|---|---|---|
Market Cap | $1.04T | $106.26B |
Volume | 3,064,878 | 30,248,434 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.28K | $108.55 |
52-Week Low | $799.57 | $78.46 |
Typical Hold Time | 93 Days | 190 Days |
Enterprise Value | $1.09T | $125.08B |
Dividend Yield | 0.59% | 2.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.
LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.
Starbucks (SBUX) trades at $93.21, down 0.4% with bearish technical signals. Recent earnings show mixed results with Q2 2026 beating expectations but Q4 2025 missing. The company is undergoing strategic restructuring with 250 store closures announced in September 2026, while maintaining dividend payments. Revenue growth remains modest at $37.18B for 2025 with net income margin at 5.17%. Analyst consensus remains positive with a $115.50 price target despite current bearish technical indicators.
SBUX presents a turnaround opportunity with strong analyst support but faces execution risks from store closures and competitive pressures. The stock trades at premium valuations (P/E 53.88) requiring sustained earnings growth. Near-term volatility expected during restructuring, while long-term prospects depend on successful portfolio optimization and international expansion, particularly in Asian markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →
